All In Biotech

Drug Trial Radar · NCT05739383

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 14,012 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

14,012

Actual

Start

Mar 9, 2023

Primary completion

Apr 16, 2029

Study completion Apr 16, 2029

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.

Conditions

  • Primary Prevention of Atherosclerotic Cardiovascular Disease

Interventions

  • Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mLDrug

    Subcutaneous injection in pre-filled syringe.

  • Placebo in 1.5mlDrug

    Matching placebo in 1.5ml solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the first occurrence of 4P-MACETime frame: Time to the first occurrence of 4P-MACE (up to approximately 75 months)

Locations

983 sites in 42 countries. Site status is shown where the registry gives one.

  • Central Alabama Research

    Birmingham, Alabama

  • UAB St Vincents

    Birmingham, Alabama

  • Eastern Shore Research Institute

    Fairhope, Alabama

  • G and L Research LLC

    Foley, Alabama

  • Longwood Research

    Huntsville, Alabama

  • CB Flock Corporation

    Mobile, Alabama

  • The Center for Clinical Trials

    Saraland, Alabama

  • Synexus

    Glendale, Arizona

  • Lenzmeier Family Practice

    Glendale, Arizona

  • Clinical Research Inst of Arizona

    Sun City West, Arizona

  • Clinical Research Advantage Fiel Family and Sports Med, PC

    Tempe, Arizona

  • Synexus Clinical Research US Inc

    Tucson, Arizona

  • Cardiovascular Res Found

    Beverly Hills, California

  • National Heart Institute

    Beverly Hills, California

  • Alliance Clinical

    Canoga Park, California

  • Inland Psychiatric Medical Group

    Chino, California

  • Valley Clinical Trials Inc

    Covina, California

  • Keck Medical Center USC

    Los Angeles, California

  • Charles R Drew University of Medicine and Science

    Los Angeles, California

  • C for Endo Diabetes and MD

    Newhall, California

  • California Medical Research Associates Inc

    Northridge, California

  • Valley Clinical Trials

    Northridge, California

  • Stanford University Medical Center

    Palo Alto, California

  • Headlands Research Sacramento

    Sacramento, California

  • Cordova Clinical Research

    Sacramento, California

  • University of California San Diego

    San Diego, California

  • Kaiser Permanente San Diego

    San Diego, California

  • Acclaim Clinical Research

    San Diego, California

  • San Diego Cardiac Center

    San Diego, California

  • Encompass Clinical Research

    Spring Valley, California

  • Harbor UCLA Medical Center

    Torrance, California

  • Cardiology Associates Medical Group

    Ventura, California

  • Blue Coast Research Center LLC

    Vista, California

  • Interv Cardiology Med Grp

    West Hills, California

  • South Denver Cardiology Associates PC

    Littleton, Colorado

  • Cardiology Ass of Fairfield County

    Stamford, Connecticut

  • Chase Medical Research LLC

    Waterbury, Connecticut

  • Excel Medical Clinical Trials LLC

    Boca Raton, Florida

  • Nova Clinical Research LLC

    Bradenton, Florida

  • Bay Care Medical Group

    Clearwater, Florida

Showing 40 of 983 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.